Medicare CED Could Support, Benefit From Surveillance Systems Like FDA’s Sentinel – McClellan
Executive Summary
At a May 16 Medicare Evidence Development and Coverage Advisory Committee meeting, former CMS and FDA Chief Mark McClellan advocated salvaging Medicare’s little-used coverage with evidence development policy for medical products.
You may also be interested in...
FDA’s Temple Sees Sentinel As Important Tool For Confirming And Analyzing Drug Adverse Events
FDA clinical science expert Robert Temple discusses how the Sentinel project – a drug data monitoring initiative – can support the agency’s postmarket drug safety investigations.
Medicare Wastage Rebate Exceptions For Small Volume Products, Cell/Gene Therapy Urged
Packaging for such products reflects ‘unique circumstances’ that should exempt them from the rebates on discarded drugs otherwise required by the policy, stakeholders tell CMS at a ‘town hall’ forum.
Pharma Gets 340B Appeals Court Victory But More Decisions Are Pending; Will Congress Step In?
Third Circuit is first of three federal appeals courts to issue a decision in multiple lawsuits over drug companies’ 340B contract pharmacy restrictions, which have led to conflicting lower court rulings on whether such restrictions are unlawful.